Yasmin Jingeloo, PhD

Harley Al-Nuaimi, M.P.

Gennady Tishchenko, M.Sc., Ph.D.

Elia Zakharov, T.M.

Alikhan Shirkhan, Ph.D.

Garry O’Sullivan, D.Sc., Ph.D.

The findings described above, together with the fact that these drugs have similar mechanism of action for the same type of lesions, suggest that these agents would be a good adjunct drugs in the treatments of Alzheimer’s disease. The fact that these agents do not appear to be toxic under normal conditions could indicate that these drugs, as compared to other anti-Alzheimer’s drugs are less susceptible to toxic effects.

The mechanism of action of the drugs which showed activity at treating mice models of AD is more clear and consistent with the actions of other agents, with both these drugs targeting the same pathway. It is possible that their actions are due to their similar mechanism of action.

The specific anti-apoptotic drugs developed might therefore prove excellent in the treatments of Alzheimer’s disease.

About the author:

Harley Al-Nuaimi, M.P. is the Professor of Psychiatry and Biobehavioral Sciences at the Department of Biomedical Engineering at the University of California, San Diego, USA. He has a long history of research involving the treatment of neurological diseases. He has been active in the field of Neuropsychiatric diseases for the past 25 years. In this course, he has described the study of the biological effects of various medications and discussed his own research on the specific mechanisms of action of various antidepressants, their possible beneficial use for AD and how it can be beneficial for the treatment of Alzheimer’s disease.

Professor Al-Nuaimi is co-editor of the journal, ‘Pharmacology of Antioxidants’. His research in the field of Alzheimer’s disease is in collaboration with Dr. Elia Zakharov, M.Sc., L.D., and Dr. Garry O’Sullivan, D.Sc.

About this course:

This course will explain how to use an advanced chemistry lab to examine a chemical compound. The subject for the course is the study of anti-apoptotic compounds (such as phenylpropanolamine (PAP) and N-acetylc